Overview

Gabapentin for the Reduction of Opiate Use Following Pulmonary Resection (GROUP Trial)

Status:
Not yet recruiting
Trial end date:
2030-07-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine if the reduction in narcotic requirement following pulmonary resection with gabapentin is clinically significant when compared to the effect seen with placebo. We have defined clinically meaningful as a reduction by 30 Morphine equivalent doses (MED)
Phase:
Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
Gabapentin